AstraZeneca’s Ultomiris has been approved by the FDA to treat rare autoimmune disease neuromyelitis optica spectrum disorder (NMOSD), six months after an earlier applicati
Infants with a rare and fatal congenital disorder called Wolman disease in England and Wales will soon have access to a new drug via the NHS that can dramatically extend t
AstraZeneca has made a sizeable play in applying artificial intelligence to drug discovery in its rare disease unit Alexion, partnering with Verge Genomics in a deal that
AstraZeneca's Soliris has become the first approved treatment in the EU for children and adolescents with generalised myasthenia gravis, a disorder that causes weakness in
Novartis has a second positive phase 3 trial in the bag for its targeted factor B inhibitor iptacopan, vying to become an oral alternative to injectable therapies for ultra-rare blood disor
US intelligence services advised the authors of the BIOSECURE Act that that WuXi AppTec shared confidential data on US customers with the Chinese government, according to